医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

An AI-based Medical Digitization Consortium in Korea Starts off Toward Digital Transformation of Global Medical Systems

2021年11月17日 PM10:30
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

“K-Avengers that join forces to accelerate AI-based medical digitization service now expand to the global market.” A large enterprise, small and medium-sized companies and startups in Korea are jointly providing medical digitization service by combining artificial intelligence and other new information technologies while accelerating the digital transformation (DX) of global medical systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117005046/en/

Lunit INSIGHT CXR, an AI-based chest X-ray analyzing solution of Lunit, enables medical professionals to detect 10 major chest diseases by reading X-ray images with an accuracy of over 97~99% in a few seconds. (Photo: Business Wire)

Lunit INSIGHT CXR, an AI-based chest X-ray analyzing solution of Lunit, enables medical professionals to detect 10 major chest diseases by reading X-ray images with an accuracy of over 97~99% in a few seconds. (Photo: Business Wire)

Korea’s National IT Industry Promotion Agency (NIPA) is promoting the project titled ‘SMEs and Large Enterprise Partnership for DNA: Data, Network, AI’. The aim of this project is to support domestic companies with innovative digital convergence technologies. Among them, the ‘SaaS-based global AI medical image analysis solution project is attracting attention; Korea’s leading IT service company LG CNS, medical AI startups Vuno and Lunit, and IT system building giant Barun Infotech have formed a consortium for this project.

Lunit INSIGHT CXR’, an AI-based chest X-ray analyzing solution of Lunit, enables medical professionals to detect 10 major chest diseases by reading X-ray images with an accuracy of over 97~99% in a few seconds. ‘VUNO Med®-Fundus AI™’, an AI-based screening solution that provides diagnostic support on common ocular diseases based on the detection of 12 retinal findings with an accuracy of over 95%. Barun Infotech plays the role of localizing AI-based medical service portal and control platform (www.globalkams.com) in line with medical systems in regions of their presence. LG CNS leads the consortium and the overseas business.

The consortium already successfully provided such medical services in an overseas market. It provided AI-based medical services at The Medical City, a large general hospital in Manila, Philippines, in three segments including chest and breast X-ray and fundus. And it obtained approval from the Filipino regulatory authorities for these services.

Now that its AI-based medical image analysis service is proved to rapidly read various diseases, including cancers and adult diseases, with an accuracy of over 90% as high as medical professionals, the consortium intends to further expand the service in overseas markets, expecting it to be an alternative for enhancing medical standards in countries and regions with insufficient medical infrastructures as well as advanced countries.

In order to preemptively respond to the 4th Industrial Revolution, NIPA is promoting various projects at home and abroad, including the ‘SMEs and Large Enterprise Partnership for DNA: Data, Network, AI’ project.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005046/en/

CONTACT

NIPA

Joonmin Park

+82-43-931-5534

pjm@nipa.kr

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Xlear与Dr. Ferrer BioPharma合作,向用户提供更佳鼻腔卫生体验
  • ネブラスカ大学医療センターとアナンダ・サイエンティフィックが心的外傷後ストレス障害(PTSD)の治療を探究する臨床試験のINDをFDAが承認と発表
  • APCER Life Sciences Expands Integrated Pharmacovigilance Services with Oracle Argus Cloud Service
  • Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
  • Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period